Tonix doses first participant in Phase 1 study of TNX-1900 for migraine and craniofacial pain

Tonix Pharmaceuticals Holding Corp.

First participant dosed in Phase 1 investigator-initiated study of TNX-1900 (intranasal potentiated oxytocin).
Study evaluates effect on trigeminal nerve-mediated vasodilation using capsaicin and electrical stimulation in healthy female volunteers.
Principal investigator Dr. Antoinette Maassen van den Brink, Erasmus University Medical Center.
TNX-1900 targets a distinct pathway from CGRP inhibitors and triptans, blocking CGRP release in animal models.
Use of Laser Speckle Contrast Imaging (LSCI) for real-time dermal blood flow measurements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.